Sinopharm Group Co Stock Key Fundamental Indicators
| SHTDF Stock | USD 2.35 0.00 0.00% |
As of the 12th of February 2026, Sinopharm Group has the Variance of 1.05, coefficient of variation of (960.29), and Risk Adjusted Performance of (0.08). In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Sinopharm Group, as well as the relationship between them. Please validate Sinopharm Group market risk adjusted performance, variance, as well as the relationship between the Variance and skewness to decide if Sinopharm Group is priced more or less accurately, providing market reflects its prevalent price of 2.35 per share. Please also confirm Sinopharm Group Co information ratio, which is currently at (0.21) to double-check the company can sustain itself at a future point.
Sinopharm Group's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Sinopharm Group's valuation are provided below:Sinopharm Group Co does not presently have any fundamental trend indicators for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Sinopharm |
Sinopharm Group 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Sinopharm Group's pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Sinopharm Group.
| 11/14/2025 |
| 02/12/2026 |
If you would invest 0.00 in Sinopharm Group on November 14, 2025 and sell it all today you would earn a total of 0.00 from holding Sinopharm Group Co or generate 0.0% return on investment in Sinopharm Group over 90 days. Sinopharm Group is related to or competes with Shanghai Pharmaceuticals, Matsumotokiyoshi, Sysmex Corp, Sonic Healthcare, Sonic Healthcare, Guangzhou Baiyunshan, and ConvaTec Group. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and heal... More
Sinopharm Group Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Sinopharm Group's pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Sinopharm Group Co upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.21) | |||
| Maximum Drawdown | 8.48 |
Sinopharm Group Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Sinopharm Group's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Sinopharm Group's standard deviation. In reality, there are many statistical measures that can use Sinopharm Group historical prices to predict the future Sinopharm Group's volatility.| Risk Adjusted Performance | (0.08) | |||
| Jensen Alpha | (0.1) | |||
| Total Risk Alpha | (0.24) | |||
| Treynor Ratio | 0.5514 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Sinopharm Group's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Sinopharm Group February 12, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.08) | |||
| Market Risk Adjusted Performance | 0.5614 | |||
| Mean Deviation | 0.3609 | |||
| Coefficient Of Variation | (960.29) | |||
| Standard Deviation | 1.02 | |||
| Variance | 1.05 | |||
| Information Ratio | (0.21) | |||
| Jensen Alpha | (0.1) | |||
| Total Risk Alpha | (0.24) | |||
| Treynor Ratio | 0.5514 | |||
| Maximum Drawdown | 8.48 | |||
| Skewness | (2.85) | |||
| Kurtosis | 16.58 |
Sinopharm Group Backtested Returns
Sinopharm Group owns Efficiency Ratio (i.e., Sharpe Ratio) of -0.11, which indicates the firm had a -0.11 % return per unit of risk over the last 3 months. Sinopharm Group Co exposes sixteen different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please validate Sinopharm Group's Risk Adjusted Performance of (0.08), coefficient of variation of (960.29), and Variance of 1.05 to confirm the risk estimate we provide. The entity has a beta of -0.21, which indicates not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Sinopharm Group are expected to decrease at a much lower rate. During the bear market, Sinopharm Group is likely to outperform the market. At this point, Sinopharm Group has a negative expected return of -0.12%. Please make sure to validate Sinopharm Group's treynor ratio and rate of daily change , to decide if Sinopharm Group performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.01 |
Very weak reverse predictability
Sinopharm Group Co has very weak reverse predictability. Overlapping area represents the amount of predictability between Sinopharm Group time series from 14th of November 2025 to 29th of December 2025 and 29th of December 2025 to 12th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Sinopharm Group price movement. The serial correlation of -0.01 indicates that just 1.0% of current Sinopharm Group price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.01 | |
| Spearman Rank Test | -0.67 | |
| Residual Average | 0.0 | |
| Price Variance | 0.01 |
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Sinopharm Group Co has a Return On Equity of 0.1319. This is 100.55% lower than that of the Healthcare sector and 98.23% lower than that of the Medical Distribution industry. The return on equity for all United States stocks is 142.55% lower than that of the firm.
Sinopharm Group Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Sinopharm Group's current stock value. Our valuation model uses many indicators to compare Sinopharm Group value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Sinopharm Group competition to find correlations between indicators driving Sinopharm Group's intrinsic value. More Info.Sinopharm Group Co is currently regarded as top stock in return on equity category among its peers. It also is currently regarded as top stock in return on asset category among its peers reporting about 0.28 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Sinopharm Group Co is roughly 3.62 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Sinopharm Group's earnings, one of the primary drivers of an investment's value.Sinopharm Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sinopharm Group's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Sinopharm Group could also be used in its relative valuation, which is a method of valuing Sinopharm Group by comparing valuation metrics of similar companies.Sinopharm Group is currently under evaluation in return on equity category among its peers.
Sinopharm Fundamentals
| Return On Equity | 0.13 | |||
| Return On Asset | 0.0364 | |||
| Profit Margin | 0.01 % | |||
| Operating Margin | 0.04 % | |||
| Current Valuation | 16.78 B | |||
| Shares Outstanding | 1.34 B | |||
| Shares Owned By Insiders | 0.01 % | |||
| Shares Owned By Institutions | 51.07 % | |||
| Price To Earning | 5.67 X | |||
| Price To Book | 0.88 X | |||
| Price To Sales | 0.01 X | |||
| Revenue | 521.05 B | |||
| Gross Profit | 44.05 B | |||
| EBITDA | 20.76 B | |||
| Net Income | 7.76 B | |||
| Cash And Equivalents | 32.15 B | |||
| Cash Per Share | 10.30 X | |||
| Total Debt | 8.42 B | |||
| Debt To Equity | 0.89 % | |||
| Current Ratio | 1.31 X | |||
| Book Value Per Share | 21.01 X | |||
| Cash Flow From Operations | 9.31 B | |||
| Earnings Per Share | 0.37 X | |||
| Price To Earnings To Growth | 49.02 X | |||
| Number Of Employees | 113.23 K | |||
| Beta | 0.72 | |||
| Market Capitalization | 8.94 B | |||
| Total Asset | 335.41 B | |||
| Retained Earnings | 11.43 B | |||
| Working Capital | 32.26 B | |||
| Current Asset | 130.51 B | |||
| Current Liabilities | 98.25 B | |||
| Z Score | 1.6 | |||
| Annual Yield | 0.05 % | |||
| Five Year Return | 3.09 % | |||
| Net Asset | 335.41 B | |||
| Last Dividend Paid | 0.75 |
About Sinopharm Group Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Sinopharm Group Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sinopharm Group using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sinopharm Group Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the Peoples Republic of China. Ltd. is a subsidiary of Sinopharm Industrial Investment Co., Ltd. Sinopharm Group is traded on OTC Exchange in the United States.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Other Information on Investing in Sinopharm Pink Sheet
Sinopharm Group financial ratios help investors to determine whether Sinopharm Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Sinopharm with respect to the benefits of owning Sinopharm Group security.